Natalizumab for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  MacDonald, J K ^b   McDonald, J W D ^b   MacDonald, John ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

Antibodies, monoclonal administration dosage; *therapeutic use ; Crohn disease *drug therapy ; Integrin alpha4; Integrins antagonists inhibitors ; Randomized controlled trials as topic; Remission induction; Treatment failure

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISOLONE; TACROLIMUS;

ABDOMINAL PAIN; ARTHRALGIA; CLINICAL TRIAL; COCHRANE LIBRARY; COLITIS; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DATA ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMBASE; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; INFECTION; MEDLINE; META ANALYSIS; NAUSEA; OUTCOMES RESEARCH; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; VOMITING;

EID: 33847632366     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006097.pub2     Document Type: Review

References (22)

1. Ghosh 2003 {published data only} Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al.Natalizumab for active Crohn's disease. N Engl J Med 2003;348(1):24-32. [MEDLINE: 12510039].
2. Gordon 2001 {published data only} Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al.A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121(2):268-74. [MEDLINE: 11487536].
3. Sandborn 2005 {published data only} Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance I, et al.Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25.
4. Targan 2006 {published data only} Targan SR, Feagan B, Fedorak R, Lashner B, Panacionne R, Present D, et al.Natalizumab induces sustained response and remission with active Crohn's disease: results fromthe ENCORE trial. Gastroenterology 2006;130(4 Suppl 2):A108.
5. Adelman 2005 Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005;353(4):432-3.
6. Alderson 2004 Alderson P, Green S, Higgens JPT, editors. Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6. The Cochrane Library 2004, Issue 1.
7. Berger 2005 Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforseen consequences. N Engl J Med 2005;353(4):414-6.
8. Brennan 2005 Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, et al.Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005;5(3):582-94.
9. Chalmers 1983 Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309(22):1358-61.
10. Hesterberg 1996 Hesterberg PE, Winsor-Hines D, Briskin MJ, Solar-Ferran D, Merrill C, Mackay CR, et al.Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111(5):1373-80. [MEDLINE: 8898653].
11. Jadad 1996 Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1- 12.
12. K-Demasters 2005 Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369-74.
13. Langer-Gould 2005 Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375-81.
14. Miller 2003 Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al.A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348(1):15-23.
15. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
16. Podolsky 1993 Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, et al.Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993;92(1):372-80. [MEDLINE: 7686922].
17. Polman 2006 Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899- 910.
18. Rudick 2006 Rudick RA, Stuart WH, Calabresi PA, Contavreux C, Galetta SL, Radue EW, et al.Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23.
19. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
20. Tubridy 1999 Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al.The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999;53(3):466-72.
21. Van Assche 2005 Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353(4):362-8.
22. Yousry 2006 Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354(9):924-33.